NeuroTherapia Completes Phase 2a Trial of Alzheimer’s Therapy NTRX-07

• NeuroTherapia, Inc. announced completion of its Phase 2a clinical trial evaluating NTRX-07 in Alzheimer’s disease patients.

• The 28-day randomized, double-masked study evaluated safety, pharmacokinetics, and biomarkers of neuroinflammation and neuronal function.

NeuroTherapia, Inc. announced completion of its Phase 2a clinical trial evaluating NTRX-07, an oral therapy for Alzheimer’s disease. The randomized, double-masked study administered NTRX-07 for 28 days and assessed safety, pharmacokinetics, and biomarkers linked to neuroinflammation and neuronal function. 

The trial also evaluated standard clinical efficacy measures, including ADAS-Cog, MMSE, and the Trail Making Test. According to the company, the study was designed to demonstrate target engagement while confirming safety and exposure levels in Alzheimer’s disease patients. 

NeuroTherapia indicated that NTRX-07 continued to demonstrate a favorable safety and tolerability profile. The company also reported that drug exposure levels were consistent with expectations, supporting continued development of the therapy. The program targets neuroinflammation, which is increasingly recognized as a key contributor to neurodegenerative disease progression. 

NTRX-07 is NeuroTherapia’s lead molecule and is being developed as an oral small-molecule therapy for neurodegenerative diseases, including Alzheimer’s disease. The completion of the Phase 2a trial represents a step toward advancing the company’s clinical development strategy and potential future trials. 

“We are pleased to see that NTRX-07 continues to be safe and well tolerated in patients with Alzheimer’s Disease, and that drug exposure levels were in line with what we expected, demonstrating a positive outcome.” 

Tony Giordano, PhD, President and Chief Executive Officer of NeuroTherapia